D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharma Reports 2024 Financial Results and Business Update
- Citius Pharmaceuticals trading halted, news pending
- Citius Pharmaceuticals reports ‘constructive’ FDA Type C meeting on Mino-Lok
- Citius Pharmaceuticals downgraded to Hold from Buy at D. Boral Capital
- Citius Pharmaceuticals announces 1-for-25 reverse stock split